Amgen, shared on LinkedIn:
“The story of innovation in small cell lung cancer (SCLC) isn’t told through a single discovery.
It’s written through years of research, collaboration, and scientific exchange.
As the oncology community comes together at WCLC26 this weekend, we’re proud to share new data across several studies in small cell lung cancer.
You may also be interested in: WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
